Capivasertib - AstraZeneca
Alternative Names: AZD 5363; TruqapLatest Information Update: 24 Jul 2024
At a glance
- Originator Astex Therapeutics; Cancer Research Technology; The Institute of Cancer Research
- Developer AstraZeneca
- Class Antineoplastics; Piperidines; Pyrimidines; Pyrroles; Small molecules
- Mechanism of Action Proto-oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HER2 negative breast cancer
- Phase III Prostate cancer; Triple negative breast cancer
- Phase II Breast cancer; Endometrial cancer; Gastric cancer; Meningioma; Non-Hodgkin's lymphoma
- Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Preclinical Diffuse large B cell lymphoma
- Discontinued Non-small cell lung cancer
Most Recent Events
- 17 Jul 2024 Registered for HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom (PO)
- 18 Jun 2024 Efficacy and safety data from the phase III CAPItello-290 trial in Breast cancer released by AstraZeneca
- 31 May 2024 Launched for HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (PO)